BML Capital Management LLC Invests $686,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

BML Capital Management LLC acquired a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in the fourth quarter, HoldingsChannel reports. The fund acquired 653,107 shares of the biotechnology company’s stock, valued at approximately $686,000. Aclaris Therapeutics makes up about 0.5% of BML Capital Management LLC’s investment portfolio, making the stock its 26th biggest holding.

A number of other institutional investors have also modified their holdings of the business. Strs Ohio grew its position in shares of Aclaris Therapeutics by 256.7% during the 4th quarter. Strs Ohio now owns 193,000 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 138,900 shares during the last quarter. Vontobel Holding Ltd. grew its position in shares of Aclaris Therapeutics by 128.8% during the 4th quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 17,040 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Aclaris Therapeutics by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,363,046 shares of the biotechnology company’s stock valued at $23,037,000 after buying an additional 33,482 shares during the last quarter. Blackstone Inc. grew its position in shares of Aclaris Therapeutics by 9,578.7% during the 3rd quarter. Blackstone Inc. now owns 1,261,425 shares of the biotechnology company’s stock valued at $8,641,000 after buying an additional 1,248,392 shares during the last quarter. Finally, Corton Capital Inc. bought a new stake in shares of Aclaris Therapeutics during the 3rd quarter valued at about $102,000. Institutional investors own 98.34% of the company’s stock.

Analyst Upgrades and Downgrades

ACRS has been the subject of a number of recent research reports. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a research report on Friday, January 12th. HC Wainwright downgraded shares of Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, January 22nd. BTIG Research reissued a “neutral” rating on shares of Aclaris Therapeutics in a research note on Thursday, January 11th. Finally, StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $22.25.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $1.22 on Wednesday. The firm has a 50-day moving average price of $1.22 and a two-hundred day moving average price of $1.84. The firm has a market capitalization of $86.53 million, a price-to-earnings ratio of -0.96 and a beta of 0.22. Aclaris Therapeutics, Inc. has a 52-week low of $0.59 and a 52-week high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. The firm had revenue of $17.57 million during the quarter, compared to analyst estimates of $3.96 million. Aclaris Therapeutics had a negative net margin of 283.15% and a negative return on equity of 64.56%. Research analysts expect that Aclaris Therapeutics, Inc. will post -0.98 earnings per share for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.